期刊
NATURE MEDICINE
卷 17, 期 9, 页码 1116-U122出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2402
关键词
-
资金
- US National Institutes of Health [CA134502, CA148164-01, K08CA122833]
- Stand Up To Cancer
- Dana Farber Harvard Cancer Center breast cancer SPORE [P50 CA089393-08S1]
- US Department of Defense [BC051565]
- V Foundation
- Claudia Barr Program
PIK3CA gain-of-function mutations are a common oncogenic event in human malignancy(1-4), making phosphatidylinositol 3-kinase (PI3K) a target for cancer therapy. Despite the promise of targeted therapy, resistance often develops, leading to treatment failure. To elucidate mechanisms of resistance to PI3K-targeted therapy, we constructed a mouse model of breast cancer conditionally expressing human PIK3CA(H1047R). Notably, most PIK3CA(H1047R)-driven mammary tumors recurred after PIK3CA(H1047R) inactivation. Genomic analyses of recurrent tumors revealed multiple lesions, including focal amplification of Met or Myc (also known as c-Met and c-Myc, respectively). Whereas Met amplification led to tumor survival dependent on activation of endogenous PI3K, tumors with Myc amplification became independent of the PI3K pathway. Functional analyses showed that Myc contributed to oncogene independence and resistance to PI3K inhibition. Notably, PIK3CA mutations and c-MYC elevation co-occur in a substantial fraction of human breast tumors. Together, these data suggest that c-MYC elevation represents a potential mechanism by which tumors develop resistance to current PI3K-targeted therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据